PL3494133T3 - Receptory limfocytów t anty-kras-g12d - Google Patents
Receptory limfocytów t anty-kras-g12dInfo
- Publication number
- PL3494133T3 PL3494133T3 PL17749580.1T PL17749580T PL3494133T3 PL 3494133 T3 PL3494133 T3 PL 3494133T3 PL 17749580 T PL17749580 T PL 17749580T PL 3494133 T3 PL3494133 T3 PL 3494133T3
- Authority
- PL
- Poland
- Prior art keywords
- kras
- cell receptors
- receptors
- cell
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369883P | 2016-08-02 | 2016-08-02 | |
| PCT/US2017/044615 WO2018026691A1 (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3494133T3 true PL3494133T3 (pl) | 2022-11-21 |
Family
ID=59564253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17749580.1T PL3494133T3 (pl) | 2016-08-02 | 2017-07-31 | Receptory limfocytów t anty-kras-g12d |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10611816B2 (pl) |
| EP (2) | EP3494133B1 (pl) |
| JP (3) | JP6993402B2 (pl) |
| KR (1) | KR102527052B1 (pl) |
| CN (2) | CN118063591A (pl) |
| AU (2) | AU2017306038B2 (pl) |
| CA (1) | CA3032870A1 (pl) |
| DK (1) | DK3494133T3 (pl) |
| ES (1) | ES2928051T3 (pl) |
| HR (1) | HRP20221183T1 (pl) |
| HU (1) | HUE060121T2 (pl) |
| IL (2) | IL301894A (pl) |
| LT (1) | LT3494133T (pl) |
| PL (1) | PL3494133T3 (pl) |
| PT (1) | PT3494133T (pl) |
| RS (1) | RS63615B1 (pl) |
| SG (2) | SG11201900654QA (pl) |
| SI (1) | SI3494133T1 (pl) |
| WO (1) | WO2018026691A1 (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3494133T3 (da) * | 2016-08-02 | 2022-09-19 | Us Health | Anti-kras-g12d-t-cellereceptorer |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| IL273254B1 (en) | 2017-09-20 | 2024-05-01 | Us Health | HLA type II-restricted T cell receptors against RAS |
| CN112638404A (zh) * | 2018-06-19 | 2021-04-09 | 百欧恩泰美国公司 | 新抗原及其用途 |
| CN113631172A (zh) * | 2019-01-25 | 2021-11-09 | 宾夕法尼亚大学理事会 | 用于靶向突变型ras的组合物和方法 |
| WO2020172332A1 (en) * | 2019-02-20 | 2020-08-27 | Fred Hutchinson Cancer Research Center | Binding proteins specific for ras neoantigens and uses thereof |
| CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
| CN112110995A (zh) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | 肿瘤新抗原多肽及其用途 |
| CN112760290A (zh) * | 2019-10-21 | 2021-05-07 | 郑州大学 | 携带突变的肿瘤驱动基因的干细胞及其用途 |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| EP4054626A4 (en) * | 2019-11-05 | 2023-11-29 | Board of Regents, The University of Texas System | HLA-RESTRICTED HORMAD1 T CELL RECEPTORS AND THEIR USES |
| MX2022007598A (es) | 2019-12-20 | 2022-09-23 | Instil Bio Uk Ltd | Dispositivos y métodos para el aislamiento de linfocitos infiltrantes de tumores y usos de los mismos. |
| JP2023508608A (ja) * | 2019-12-30 | 2023-03-02 | ブリスター イムノテック カンパニー リミテッド | 強化されたｔ細胞受容体ｓｔａｒ及びその用途 |
| KR20230043881A (ko) * | 2020-07-13 | 2023-03-31 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | G12d 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 drb t 세포 수용체 |
| EP4251177A2 (en) * | 2020-11-25 | 2023-10-04 | Geneius Biotechnology, Inc. | Antigen specific t cells and methods of making and using same |
| EP4298121A1 (en) | 2021-02-25 | 2024-01-03 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| TW202309071A (zh) | 2021-05-05 | 2023-03-01 | 德商英麥提克生物技術股份有限公司 | 特異性結合ｐｒａｍｅ之抗原結合蛋白 |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| CN114920823B (zh) * | 2022-05-27 | 2023-10-17 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| WO2024020537A2 (en) * | 2022-07-22 | 2024-01-25 | Board Of Regents, The University Of Texas System | Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
| US20020150891A1 (en) * | 1994-09-19 | 2002-10-17 | Leroy E. Hood | Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region |
| US7709002B1 (en) | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| DK1545204T3 (en) | 2002-09-06 | 2016-11-14 | The Government Of The Us Secretary Dept Of Health And Human Services | Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy |
| US8216565B2 (en) | 2007-01-12 | 2012-07-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | GP100-specific T cell receptors and related materials and methods of use |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| SI2618835T1 (sl) | 2010-09-20 | 2017-10-30 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t celični receptorji in t celični epitopi |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| ES2689512T3 (es) * | 2011-09-15 | 2018-11-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Receptores de células T que reconocen MAGE restringido por HLA-A1 o a HLA-Cw7 |
| CA2853645A1 (en) * | 2011-11-30 | 2013-06-06 | National Cancer Center | Induced malignant stem cells |
| SG11201509742QA (en) * | 2013-06-03 | 2015-12-30 | Novartis Ag | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
| GB201313377D0 (en) * | 2013-07-26 | 2013-09-11 | Adaptimmune Ltd | T cell receptors |
| GB201314404D0 (en) * | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| EP4286407A3 (en) * | 2014-11-26 | 2024-03-06 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-mutated kras t cell receptors |
| AU2016323017B2 (en) * | 2015-09-15 | 2020-11-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing HLA-Cw8 restricted mutated KRAS |
| DK3494133T3 (da) * | 2016-08-02 | 2022-09-19 | Us Health | Anti-kras-g12d-t-cellereceptorer |
-
2017
- 2017-07-31 DK DK17749580.1T patent/DK3494133T3/da active
- 2017-07-31 CN CN202410214235.4A patent/CN118063591A/zh active Pending
- 2017-07-31 IL IL301894A patent/IL301894A/en unknown
- 2017-07-31 PL PL17749580.1T patent/PL3494133T3/pl unknown
- 2017-07-31 IL IL264425A patent/IL264425B2/en unknown
- 2017-07-31 LT LTEPPCT/US2017/044615T patent/LT3494133T/lt unknown
- 2017-07-31 ES ES17749580T patent/ES2928051T3/es active Active
- 2017-07-31 EP EP17749580.1A patent/EP3494133B1/en active Active
- 2017-07-31 PT PT177495801T patent/PT3494133T/pt unknown
- 2017-07-31 CN CN201780059356.4A patent/CN109790211B/zh active Active
- 2017-07-31 EP EP22182473.3A patent/EP4159751A1/en active Pending
- 2017-07-31 CA CA3032870A patent/CA3032870A1/en active Pending
- 2017-07-31 SI SI201731231T patent/SI3494133T1/sl unknown
- 2017-07-31 SG SG11201900654QA patent/SG11201900654QA/en unknown
- 2017-07-31 SG SG10201913959WA patent/SG10201913959WA/en unknown
- 2017-07-31 US US16/321,899 patent/US10611816B2/en active Active
- 2017-07-31 KR KR1020197005837A patent/KR102527052B1/ko active IP Right Grant
- 2017-07-31 JP JP2019505220A patent/JP6993402B2/ja active Active
- 2017-07-31 HR HRP20221183TT patent/HRP20221183T1/hr unknown
- 2017-07-31 WO PCT/US2017/044615 patent/WO2018026691A1/en unknown
- 2017-07-31 AU AU2017306038A patent/AU2017306038B2/en active Active
- 2017-07-31 HU HUE17749580A patent/HUE060121T2/hu unknown
- 2017-07-31 RS RS20220894A patent/RS63615B1/sr unknown
-
2020
- 2020-04-02 US US16/838,395 patent/US11208456B2/en active Active
-
2021
- 2021-06-11 US US17/345,390 patent/US11897933B2/en active Active
- 2021-12-03 US US17/541,619 patent/US11840561B2/en active Active
- 2021-12-09 JP JP2021199878A patent/JP7413338B2/ja active Active
-
2023
- 2023-09-21 AU AU2023233125A patent/AU2023233125A1/en active Pending
- 2023-12-27 JP JP2023221526A patent/JP2024045139A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262144A (en) | t cell receptors | |
| ZA201806866B (en) | T cell receptors | |
| ZA201806862B (en) | T cell receptors | |
| IL271435A (en) | t cell receptors | |
| ZA201806865B (en) | T cell receptors | |
| IL264425B1 (en) | t cell receptors against kras-g20 | |
| IL251524B (en) | t cell receptors | |
| GB201522592D0 (en) | T cell receptors | |
| HUE064591T2 (hu) | T-sejt receptorok | |
| EP3529267C0 (en) | T CELL RECEPTOR | |
| GB201518991D0 (en) | T cell receptors |